Open-label evaluation of the novel antipsychotic compound BW234U in chronic schizophrenics.

Journal Article (Academic article)

In a 28-day open label study, 15 inpatients with chronic schizophrenia in relapse were treated with BW234U. Approximately half of the patients showed marked improvement. Four patients showed no change and three dropped out. Thought disturbance improved markedly. The compound was tolerated very well.

Full Text

Duke Authors

Cited Authors

  • Schwarcz, G; Halaris, A; Dren, A; Manberg, P

Published Date

  • 1985

Published In

  • Drug Development Research

Volume / Issue

  • 5 / 4

Start / End Page

  • 387 - 393

Digital Object Identifier (DOI)

  • 10.1002/ddr.430050412